FDA's con­tro­ver­sial OK for eteplirsen spurs sec­ond thoughts for a re­ject­ed ri­val at Bio­Marin

Sarep­ta’s reg­u­la­to­ry win for Ex­ondys51 (eteplirsen) left one group of an­a­lysts and FDA in­sid­ers more than a lit­tle flab­ber­gast­ed.

There was on­ly a mi­nus­cule amount of da­ta to look at. And af­ter all, PTC nev­er even got in the doors at the FDA, while the agency had no trou­ble slap­ping down Bio­Marin’s ap­pli­ca­tion for dris­apersen, which had more da­ta — in­clud­ing its fail­ure in clin­i­cal stud­ies and trou­bling safe­ty signs.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA